Rami Manochakian

Rami Manochakian: U.S. FDA approves Amivantamab WITH CHEMOTHERAPY for 1st Line treatment of advanced non-small cell Lung Cancer with EGFR

Rami Manochakian, Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:

“HOT OFF THE PRESS

U.S. FDA approves Amivantamab WITH CHEMOTHERAPY for 1stLine treatment of advanced non-small cell Lung Cancer with EGFR Exon20 mutations. Approval based on Papillion trial which showed increased mPFS compared with chemo alone: 11.4 vs 6.7 months.”

Rami Manochakian: U.S. FDA approves Amivantamab WITH CHEMOTHERAPY for 1st Line treatment of advanced non-small cell Lung Cancer with EGFR Rami Manochakian: U.S. FDA approves Amivantamab WITH CHEMOTHERAPY for 1st Line treatment of advanced non-small cell Lung Cancer with EGFR

Source: Rami Manochakian/X

Amivantamab cancer Lung cancer non small cell lung cancer OncoDaily Oncology Papillion trial Rami Manochakian